References
- Brice P. Managing relapsed and refractory Hodgkin lymphoma. Br J Haematol 2008;141:3–13.
- Appelbaum FR. Hematopoietic cell transplantation for non-Hodgkin's lymphoma: yesterday, today, and tomorrow. J Clin Oncol 2008;26:2927–2929.
- Kaplan LD, Swaus DJ, Testa MA, et al. Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. N Engl J Med 1997;336:1641–1648.
- Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993;328: 1002–1006.
- The Subspecialty Group of Hematology; Pediatric Society; Chinese Medical Association. The diagnosis and treatment recommendations of childhood acute lymphoblastic leukemia. Chin J Pediatr 2006;44:392–395.
- Shen ZX, editor. Special issue on diagnosis and treatment of lymphoma. Shanghai: Shanghai Science and Technology Press; 2007. pp 137–138.
- Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 2010;28:4184—4190.
- Shi KY, editor. Lymphomas. Beijing: Peking University Medical Press; 2007. p 368.
- Velasquez WS, McLaughlin P, Tucker S, et al. ESHAP--an effective chemotherapy regimen in refractory and elapsing lymphoma: a 4-year follow-up study. J Clin Oncol 1994;12:1169–1176.
- Velasquez WS, Cabanillas F, Salvador P, et al. Effective salvage therapy for lymphoma with cisplatin in combination with highdose Ara-C and dexamethasone (DHAP). Blood 1988;71:117–122.
- Rodriguez MA, Cabanillas FC, Hagemeister FB, et al. A phase II trial of mesna/ifosfamide, mitoxantrone and etoposide for refractory lymphomas. Ann Oncol 1995;6:609–611.
- Moskowitz CH, Bertino JR, Glassman JR, et al. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol 1999;17:3776–3785.
- Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 2010;28:4184–4190.
- Hagberg H, and Gisselbrecht C. Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: an update of the CORAL study. Ann Oncol 2006;17:31–32.
- Martín A, Conde E, Arnan M, et al. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. Haematologica 2008;93:1829–1836.
- Xun SY, editor. Chinese Journal of Clinical Pharmacology. Beijing: People's Medical Press; 2003. pp 1453–1457.
- Bredenfeld H, Franklin J, Nogova L, et al. Severe pulmonary toxicity in patients with advanced-stage Hodgkin's disease treated with a modified bleomycin, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone, and gemcitabine (BEACOPP) regimen is probably related to the combination of gemcitabine and bleomycin: a report of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2004;22:2424–2429.